You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

248 Results
Drug
Other Name(s): Gemzar®
Dec 1969
Drug
Other Name(s): Columvi®
Sep 2024
Drug
Other Name(s): Epkinly™
Nov 2024
Guidelines and Advice
Nov 2024
Cancer screening can find abnormal cell changes before they become cancer or cancer at an early stage, when treatment has a better chance of working...
Drug
Other Name(s): Iressa®
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Guidelines and Advice
Status: Current
ID: GL 20-2
Version: 2
Dec 1969
Guidelines and Advice

Pages